They already passed the safety look, the one that Eli Lilly just missed. This is a full interim review, including efficacy. Doubt that the safety results would have changed since the safety look, so this is all about whether there is high enough certainty about efficacy to halt at midterm or whether instead (as most cases go) this goes to full trial end.